M1FG
ICPT

Mach-1 Financial Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Mach-1 Financial Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed – – 219
2021
Q1 		$0 Buy
+2
New +$56 ﹤0.01% 241

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mach-1 Financial Group's ICPT Position: Q2 2021 in Review

Mach-1 Financial Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 2 shares.

Mach-1 Financial Group first reported a position in ICPT in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Mach-1 Financial Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Mach-1 Financial Group sold 2 Intercept Pharmaceuticals, Inc. shares in Q2 2021.
  • Mach-1 Financial Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Mach-1 Financial Group's Intercept Pharmaceuticals, Inc. position peaked at $0 in Q1 2021.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Mach-1 Financial Group's 13F filing for Q2 2021, filed 4 Aug 2021.